Irbesartan - Sanofi aventis

Drug Profile

Irbesartan - Sanofi aventis

Alternative Names: Aprovel; Avapro; BMS 186295; Irbetan; Karvea; SR 47436; Xarb

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; Sanofi; sanofi-aventis; Shionogi
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension
  • No development reported Atrial fibrillation
  • Discontinued Atherosclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Jan 2018 No development reported - Phase-II for Atrial fibrillation (Prevention) in Japan (PO)
  • 31 Mar 2016 Shionogi completes a phase II trial in Atrial fibrillation in Japan (UMIN000005205)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top